MedTrace Logo

Compliance of Patients With Essential Hypertension Treated With Candesartan or Candesartan/Hydrochlorothiazide

NCT00608153 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1773

Last updated 2008-02-06

No results posted yet for this study

Summary

The CoCa study with at maximum daily dose of 32 mg candesartan or 16/12.5 mg candesartan/hydrochlorothiazide has the objective to evaluate under naturalistic conditions, i.e. under routine medical care conditions, the subject compliance as well as the efficacy and tolerability of candesartan or candesartan/HCT in subjects suffering from essential hypertension.

Conditions

  • Essential Hypertension

Sponsors & Collaborators

Principal Investigators

  • R. E. Schmieder, MD · University hospital Erlangen-Nurnberg

  • Andrea Pahor, MD · MED Dep., AstraZeneca Germany

Eligibility

Sex
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-01-31
Completion
2007-09-30

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00608153 on ClinicalTrials.gov